In mouse models of metastatic melanoma, an anti-tumor activity of ILC2s activated by IL-33 has been shown; in this case, ILC2 cells release IL-5, which in turn recruits eosinophils exerting an anti-tumor activity [108], as also described in CRC [109]. Here, IL33 is linked to neoplasm.